SAN DIEGO, Sept. 21 /PRNewswire/ — Aethlon Medical, Inc. (OTC
AEMD), the pioneer in developing therapeutic filtration devices
to address infectious disease and cancer, disclosed today that it
has reestablished efforts to advance the Aethlon Hemopurifier®
within U.S. Government programs that support the development and
purchase of treatment countermeasures against bioterror threats.
The Aethlon Hemopurifier® is the first medical device to
selectively target the removal of infectious viruses and
immunosuppressive proteins from the entire circulatory system.
Based on studies conducted by government and non-government
research organizations, Aethlon believes the Hemopurifier®
represents the most advanced and perhaps the only true
broad-spectrum countermeasure against viral threats most likely to
be weaponized against civilian and military populations.
Therapeutics able to target multiple bioterror threats have
become a focal point of the U.S. Health and Human Services
Department (HHS) and dual-use therapies such as the
Hemopurifier®, that also have commercial applications against
established disease conditions such as hepatitis-C virus (HCV) and
cancer, are no longer precluded from consideration to be supported
by government programs.
“Revamped government policies expand the opportunity for our
Hemopurifier® in the United States and improve our potential
access to non-dilutive capital resources, which are not capped by
the public market value of our organization,” stated Aethlon
Chairman and CEO, Jim Joyce. “We now plan to upda